Advertisement

Current picture of anaplastic thyroid cancer patients' care and meetable needs: A survey of 94 Institutions from the EORTC Endocrine and Head and Neck Cancer Groups

Published:January 02, 2023DOI:https://doi.org/10.1016/j.ejca.2022.12.002

      Highlights

      • Anaplastic thyroid carcinoma is poorly responsive to chemotherapy and highly lethal.
      • BRAF/MEKi and immunotherapy have shown promising results in certain subsets of ATC.
      • International guidelines recommend molecular testing to address appropriate therapy.
      • In Europe, no innovative treatments have been approved recently for advanced ATC.
      • This survey captures the diversified scenario of ATC diagnosis/therapy across E.U.

      Abstract

      Anaplastic thyroid carcinoma (ATC) is a rare cancer accounting for 40% of thyroid cancer-specific deaths. In the last 5 years, improved insights into molecular pathways led the Food and Drug Administration to license BRAF/MEK inhibitors (B/Mi) in BRAFV600E-mutant ATC, and pembrolizumab in solid cancer with high tumour mutational burden (TMB-H) (≥10 mutations/megabase) (mut/Mb). In Europe, clinicians face challenges in prescribing novel treatments, as the European Medical Association (EMA) has not licensed B/Mi nor immunotherapy (IO) for ATC so far. Some patients manage to receive these drugs through alternative ways. We investigated the extent of this phenomenon launching an online survey from March 12th to 19th 2021 open to 239 Institutions in the EORTC Endocrine and Head & Neck Cancer Groups. Questions enquired about the number of ATC patients evaluated/year, feasibility of BRAF assessment, accessibility to B/Mi-IO, availability of clinical trials and interest in new studies. Colleagues from 94 Institutions (20 Countries) joined: 30 centres evaluated ≥5 ATC patients/year, with an overall incidence >200 patients/year. 80.8% tested BRAF status, 43.6% by next-generation sequencing. 62.7% and 70% of responders reported limitations in prescribing B/Mi and IO, respectively: either the impossibility of offering them, or drugs accessibility exclusively under certain conditions (e.g. health insurance, clinical trials, compassionate use, off-label). Only 13.8% had clinical trials ongoing while 91.5% of sites claimed ATC-dedicated trials. Disparities in access to novel treatments are diffuse. Access to cutting-edge therapies is an urgent issue in this setting, and clinical trials seem feasible within an appropriate network.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Filetti S.
        • Durante C.
        • Hartl D.
        • Leboulleux S.
        • Locati L.D.
        • Newbold K.
        • et al.
        Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2019 Dec; 30: 1856-1883
        • Lin B.
        • Ma H.
        • Ma M.
        • Zhang Z.
        • Sun Z.
        • Hsieh I.Y.
        • et al.
        The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis.
        Am J Transl Res. 2019; 11: 5888-5896
        • Kong N.
        • Xu Q.
        • Zhang Z.
        • Cui A.
        • Tan S.
        • Bai N.
        Age influences the prognosis of anaplastic thyroid cancer patients.
        Front Endocrinol [Internet]. 2021; 12 ([cited 2022 Oct 8]. Available from:)
        • Maniakas A.
        • Dadu R.
        • Busaidy N.L.
        • Wang J.R.
        • Ferrarotto R.
        • Lu C.
        • et al.
        Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019.
        JAMA Oncol. 2020 Sep 1; 6: 1397-1404
        • Cabanillas M.E.
        • Ahmed S.
        • Wang J.R.
        Management of anaplastic and recurrent differentiated thyroid cancer: indications for surgical resection, molecular testing, and systemic therapy.
        Neuroimaging Clin N Am. 2021 Aug 1; 31: 359-366
        • Xu B.
        • Fuchs T.
        • Dogan S.
        • Landa I.
        • Katabi N.
        • Fagin J.A.
        • et al.
        Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases.
        Thyroid. 2020 Oct; 30: 1505-1517
        • Pozdeyev N.
        • Gay L.M.
        • Sokol E.S.
        • Hartmaier R.
        • Deaver K.E.
        • Davis S.
        • et al.
        Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers.
        Clin Cancer Res. 2018 Jul 1; 24: 3059-3068
        • Yoo S.K.
        • Song Y.S.
        • Lee E.K.
        • Hwang J.
        • Kim H.H.
        • Jung G.
        • et al.
        Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
        Nat Commun. 2019 Jun 24; 10: 2764
        • Subbiah V.
        • Kreitman R.J.
        • Wainberg Z.A.
        • Cho J.Y.
        • Schellens J.H.M.
        • Soria J.C.
        • et al.
        Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer.
        J Clin Oncol. 2018 Jan 1; 36: 7-13
        • Subbiah V.
        • Kreitman R.J.
        • Wainberg Z.A.
        • Cho J.Y.
        • Schellens J.H.M.
        • Soria J.C.
        • et al.
        Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
        Ann Oncol. 2022 Apr; 33: 406-415
        • Cantara S.
        • Bertelli E.
        • Occhini R.
        • Regoli M.
        • Brilli L.
        • Pacini F.
        • et al.
        Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.
        Endocrine. 2019 Apr; 64: 122-129
        • Capdevila J.
        • Wirth L.J.
        • Ernst T.
        • Ponce Aix S.
        • Lin C.C.
        • Ramlau R.
        • et al.
        PD-1 blockade in anaplastic thyroid carcinoma.
        JCO. 2020 Aug 10; 38: 2620-2627
        • Dierks C.
        • Ruf J.
        • Seufert J.
        • Kreissl M.
        • Klein C.
        • Spitzweg C.
        1646MO - Phase II ATLEP trial: final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma.
        in: Paris: Annals of Oncology (2022). 2022
        • Cabanillas M.E.
        • Dadu R.
        • Ferrarotto R.
        • Liu S.
        • Fellman B.M.
        • Gross N.D.
        • et al.
        Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC).
        JCO. 2020 May 20; 38: 6514
        • Lorch J.H.
        • Barletta J.A.
        • Nehs M.
        • Uppaluri R.
        • Alexander E.K.
        • Haddad R.I.
        • et al.
        A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).
        JCO. 2020 May 20; 38: 6513
        • Dierks C.
        • Seufert J.
        • Aumann K.
        • Ruf J.
        • Klein C.
        • Kiefer S.
        • et al.
        Combination of Lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma.
        Thyroid. 2021 Jul; 31: 1076-1085
        • Maio M.
        • Ascierto P.A.
        • Manzyuk L.
        • Motola-Kuba D.
        • Penel N.
        • Cassier P.A.
        • et al.
        Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.
        Ann Oncol. 2022 Sep; 33: 929-938
        • Mulder J.
        • van Stuijvenberg O.C.
        • van Hennik P.B.
        • Voest E.E.
        • Pasmooij A.M.G.
        • Stoyanova-Beninska V.
        • et al.
        A comparison of post-marketing measures imposed by regulatory agencies to confirm the tissue-agnostic approach.
        Front Med (Lausanne). 2022 Jun 14; 9893400
        • Filetti S.
        • Durante C.
        • Hartl D.M.
        • Leboulleux S.
        • Locati L.D.
        • Newbold K.
        • et al.
        ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.
        Ann Oncol. 2022 Jul; 33: 674-684
        • Choden S.
        • Keelawat S.
        • Jung C.K.
        • Bychkov A.
        VE1 immunohistochemistry improves the limit of genotyping for detecting BRAFV600E mutation in papillary thyroid cancer.
        Cancers (Basel). 2020 Mar 5; 12: 596
        • Capdevila J.
        • Awada A.
        • Führer-Sakel D.
        • Leboulleux S.
        • Pauwels P.
        Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era.
        Cancer Treat Rev. 2022 May; 106102380
        • Pruneri G.
        • De Braud F.
        • Sapino A.
        • Aglietta M.
        • Vecchione A.
        • Giusti R.
        • et al.
        Next-generation sequencing in clinical practice: is it a cost-saving alternative to a single-gene testing approach?.
        Pharmacoecon Open. 2021 Jun; 5: 285-298
        • Schwarze K.
        • Buchanan J.
        • Taylor J.C.
        • Wordsworth S.
        Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature.
        Genet Med. 2018 Oct; 20: 1122-1130
        • Mosele F.
        • Remon J.
        • Mateo J.
        • Westphalen C.B.
        • Barlesi F.
        • Lolkema M.P.
        • et al.
        Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
        Ann Oncol. 2020 Nov; 31: 1491-1505
        • Garcia-Alvarez A.
        • Hernando J.
        • Carmona-Alonso A.
        • Capdevila J.
        What is the status of immunotherapy in thyroid neoplasms?.
        Front Endocrinol (Lausanne). 2022 Aug 5; 13929091
        • Blay J.Y.
        • Coindre J.M.
        • Ducimetière F.
        • Ray-Coquard I.
        The value of research collaborations and consortia in rare cancers.
        Lancet Oncol. 2016 Feb; 17: e62-e69
        • Komatsubara K.M.
        • Carvajal R.D.
        The promise and challenges of rare cancer research.
        Lancet Oncol. 2016 Feb; 17: 136-138